A Study of LY2969822 in Healthy Participants

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate how safe LY2969822 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. This is the first time that this study drug is being given to participants. This study is for research purposes only and is not intended to treat any medical condition.

Clinical Trial Description

Participants in Part A will complete three study periods, which together will last about 40 days. Participants in Parts B and C will complete one study period which will last about 17 days, but the total study time is about 40 days. Each participant may only enroll in one part. Screening is required within 28 days prior to the start of the study for all participants. ;

Study Design

Related Conditions & MeSH terms

Healthy Volunteers

Clinical Trial Details

NCT number	NCT02018887
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 1
Start date	December 2013
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05029518` - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability	Phase 1
Completed	`NCT05001152` - Taste Assessment of Ozanimod	Phase 1
Completed	`NCT04493255` - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants	Phase 1
Completed	`NCT03457649` - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers	Phase 1
Completed	`NCT00995891` - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed	`NCT05050318` - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively	Phase 4
Completed	`NCT05043766` - Evaluation of Oral PF614 Relative to OxyContin	Phase 1
Completed	`NCT04466748` - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects	Phase 1
Completed	`NCT00746733` - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC	Phase 1
Recruiting	`NCT05929651` - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy	Phase 4
Completed	`NCT05954039` - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect	N/A
Completed	`NCT05045716` - A Study of Subcutaneous Lecanemab in Healthy Participants	Phase 1
Active, not recruiting	`NCT02747927` - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children	Phase 3
Completed	`NCT05533801` - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants	Phase 1
Not yet recruiting	`NCT03931369` - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)	Phase 2
Completed	`NCT03279146` - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects	Phase 1
Completed	`NCT06027437` - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants	Phase 1
Recruiting	`NCT05619874` - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity	N/A
Completed	`NCT05553418` - Investigational On-body Injector Clinical Study	N/A
Completed	`NCT04092712` - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers	Phase 1